2. Disease Areas
  3. Musculoskeletal Disease
  4. Arthritis Spinal Disease
  5. Ankylosing Spondylitis

Ankylosing Spondylitis

Ankylosing spondylitis, also known as axial spondyloarthritis, is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, leading to pain, stiffness, and eventually spinal fusion due to progressive ankylosis. It is strongly associated with the HLA-B27 genetic variant and typically begins in young adulthood. The condition causes persistent inflammation in the spine and peripheral joints, resulting in impaired mobility and reduced quality of life. While it affects both sexes, it is more prevalent in males. Early diagnosis and management are crucial to prevent structural damage and maintain functional capacity.

Ankylosing Spondylitis (4):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N7700A
    Guluronic acid sodium 98.0%
    Guluronic acid (G2013) sodium is an orally active oxidative stress regulator and anti-inflammatory agent that exerts pharmacological effects by down-regulating various pro-inflammatory and oxidative stress-related genes (such as TLR4, NF-κB, iNOS, etc.) and inhibiting the activities of COX-2, MMPs and VEGF. Low-dose Guluronic acid sodium up-regulates the expression of immunoregulatory genes SHIP1 and SOCS1, thereby effectively inhibiting cancer-related inflammation, tumor angiogenesis, cell adhesion and metastasis, while reducing the accumulation of immunosuppressive cells. Guluronic acid sodium significantly prolongs the survival time of tumor-bearing hosts within a concentration range without direct cytotoxicity, demonstrating favorable safety. Guluronic acid sodium has involved in the research of multiple sclerosis, ankylosing spondylitis, breast cancer and other inflammatory diseases.
    Guluronic acid sodium
  • HY-N7700
    Guluronic acid 15769-56-9 98.90%
    Guluronic acid (G2013) is an orally active oxidative stress regulator and anti-inflammatory agent that exerts pharmacological effects by down-regulating various pro-inflammatory and oxidative stress-related genes (such as TLR4, NF-κB, iNOS, etc.) and inhibiting the activities of COX-2, MMPs and VEGF. Low-dose Guluronic acid up-regulates the expression of immunoregulatory genes SHIP1 and SOCS1, thereby effectively inhibiting cancer-related inflammation, tumor angiogenesis, cell adhesion and metastasis, while reducing the accumulation of immunosuppressive cells. Guluronic acid significantly prolongs the survival time of tumor-bearing hosts within a concentration range without direct cytotoxicity, demonstrating favorable safety. Guluronic acid has involved in the research of multiple sclerosis, ankylosing spondylitis, breast cancer and other inflammatory diseases.
    Guluronic acid
  • HY-P99335
    Vunakizumab 1792181-33-9
    Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody and an Interleukin-17A (IL-17A) inhibitor. Vunakizumab binds to IL-17A to inhibit downstream cytokines and block inflammatory signaling. Vunakizumab can be used for the research of chronic plaque psoriasis and ankylosing spondylitis.
    Vunakizumab
  • HY-P99754
    Netakimab 1796570-08-5
    Netakimab (BCD-085) is a humanized IgG1κ monoclonal anti-IL-17 antibody that binds to and blocks IL-17 and IL-17A activity, including reduction of downstream IL-6 production. Netakimab can be used for the research of moderate-to-severe plaque psoriasis, ankylosing spondylitis, and COVID-19 with cytokine release syndrome. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Netakimab